

<b>Reference:</b>	FOI.20594.26
<b>Subject:</b>	Breast Cancer
<b>Date of Request:</b>	3 June 2026

**Requested:**

1. How many patients have been treated for breast cancer (any stage) in the past 3 months with the following systemic anti-cancer therapies:

- Abemaciclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)
- Abemaciclib + Fulvestrant
- Alpelisib + Fulvestrant
- Anthracycline (e.g. doxorubicin or epirubicin) + Cyclophosphamide only
- Anthracycline (e.g. doxorubicin or epirubicin) + Cyclophosphamide + Paclitaxel
- Atezolizumab
- Capivasertib
- Capecitabine as a single agent
- Carboplatin + Paclitaxel
- Elacestrant
- Eribulin as a single agent or in combination
- Everolimus + Exemestane
- Fulvestrant as a single agent
- Palbociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)
- Palbociclib + Fulvestrant
- Parp Inhibitors (Olaparib/Talazoparib)
- Pembrolizumab Monotherapy
- Pembrolizumab + Anthracycline (e.g. doxorubicin or epirubicin) + Cyclophosphamide
- Carboplatin + Paclitaxel + Pembrolizumab
- Pertuzumab (Perjeta) + Trastuzumab (Herceptin)
- Phesgo (Pertuzumab + Trastuzumab in a single injection)
- Ribociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)
- Ribociclib + Fulvestrant
- Sacituzumab Govitecan
- Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent
- Trastuzumab deruxtecan (Enhertu)
- Trastuzumab (Herceptin) as a single agent or in combination with Paclitaxel
- Trastuzumab emtansine (Kadcyla)
- Any other active systemic anti-cancer therapy
- Pembrolizumab subcutaneous injection

2. In the past 3 months, how many patients have been treated with the following systemic anti-cancer therapies for breast cancer (please indicate whether they were treated for early or metastatic disease):

	Total Patients	Early Patients	Metastatic Patients
Phesgo (Pertuzumab + Trastuzumab in a single injection)			
Pertuzumab (Perjeta) + Trastuzumab (Herceptin)			

Trastuzumab (Herceptin) as a single agent or in combination with Paclitaxel			
Trastuzumab deruxtecan (Enhertu)			
Trastuzumab emtansine (Kadcyla)			
Abemaciclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)			
Abemaciclib + Fulvestrant			
Ribociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)			
Ribociclib + Fulvestrant			
Capecitabine as a single agent			
Carboplatin + Paclitaxel			
Carboplatin + Paclitaxel + Pembrolizumab			

3. Does your trust participate in any clinical trials for breast cancer? If so, please provide the name of each trial, and the number of patients taking part.

**Response:**

Hywel Dda University Health Board (UHB) is unable to provide you with the exact number of patients, due to the low number (less than 5) and have therefore, replaced the figures in the tables with an asterisk (\*), as there is a potential risk of identifying individuals if this was disclosed. The UHB has also replaced the figures and totals which could be used to calculate the redacted figures with a double asterisk (\*\*). The UHB is therefore withholding this detail under Section 40(2) of the Freedom of Information Act (FoIA). This information is protected by the Data Protection Act 2018 (DPA)/UK General Data Protection Regulations (UK GDPR) as its disclosure would constitute unfair and unlawful processing and would be contrary to the principles and articles of the UK GDPR. This exemption is absolute and therefore, there is no requirement to apply the public interest test.

In reaching this decision, the DPA and UK GDPR define personal data as data that relates to a living individual who can be identified solely from that data or from that data and other information, which is in the possession of the data controller.

Additionally, some of the therapies listed are recorded together on the ChemoCare system and are unable to be split; therefore, the information has been provided as recorded on the ChemoCare system.

1. The UHB provides within the table below, the number of patients that have been treated for breast cancer (any stage), with the listed Systemic Anti-Cancer Therapies (SACTs), during the period 1 March 2025 to 31 May 2026.

SACT	Number
Abemaciclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)	0
Abemaciclib + Fulvestrant	28
Alpelisib + Fulvestrant	0
Anthracycline (e.g. doxorubicin or epirubicin) + Cyclophosphamide only	0
Anthracycline (e.g. doxorubicin or epirubicin) + Cyclophosphamide + Paclitaxel	0
Atezolizumab	0
Capivasertib	0

Capecitabine as a single agent	19
Carboplatin + Paclitaxel	9
Elacestrant	*
Eribulin as a single agent or in combination	5
Everolimus + Exemestane	*
Fulvestrant as a single agent	6
Palbociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)	49
Palbociclib + Fulvestrant	0
Parp Inhibitors (Olaparib/Talazoparib)	*
Pembrolizumab Monotherapy	*
Pembrolizumab + Anthracycline (e.g. doxorubicin or epirubicin) + Cyclophosphamide	16
Carboplatin + Paclitaxel + Pembrolizumab	9
Pertuzumab (Perjeta) + Trastuzumab (Herceptin)	33
Phesgo (Pertuzumab + Trastuzumab in a single injection)	55
Ribociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)	50
Ribociclib + Fulvestrant	6
Sacituzumab Govitecan	6
Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent	0
Trastuzumab deruxtecan (Enhertu)	11
Trastuzumab (Herceptin) as a single agent or in combination with Paclitaxel	6
Trastuzumab emtansine (Kadcyla)	10
Any other active Aystemic Anti-Cancer Therapy (SACT)	25
Pembrolizumab subcutaneous injection	*

2. The UHB provides within the table overleaf, the number of patients treated with the listed SACTs for breast cancer, by stage, during the period 1 March 2025 to 31 May 2026.

SACT	Early	Metastatic	Total
Phesgo (Pertuzumab + Trastuzumab in a single injection)	33	22	55
Pertuzumab (Perjeta) + Trastuzumab (Herceptin)	22	11	33
Trastuzumab (Herceptin) as a single agent or in combination with Paclitaxel	6	0	6
Trastuzumab deruxtecan (Enhertu)	0	11	11
Trastuzumab emtansine (Kadcyla)	**	*	10
Abemaciclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)	0	0	0
Abemaciclib + Fulvestrant	**	*	28
Ribociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)	25	25	50
Ribociclib + Fulvestrant	0	6	6
Capecitabine as a single agent	*	0	**
Carboplatin + Paclitaxel	*	0	**
Carboplatin + Paclitaxel + Pembrolizumab	9	0	9

3. The UHB is currently participating in clinical trials for breast cancer and provides the names of the trials and numbers of patients partaking in each, within the table below.

<b>Name</b>	<b>Details</b>	<b>Number</b>
ATNEC	Non-drug clinical trial: Axillary management in T1-3N1M0 breast cancer patients with needle biopsy proven nodal metastases at presentation after neoadjuvant chemotherapy. Status: open to recruitment.	8
BECA	Study limited to working with human tissue samples: Omics approaches to improve the diagnosis, management and treatment of breast cancer. Status: open to recruitment.	76